Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, Takizawa M. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. J Neurochem. 2011 Dec;119(6):1330-40. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. This is indirect evidence for the role of tau phosphorylation in the cognitive deficit in AD.

    View all comments by Takaomi Saido

  2. The localization data generated with Dendra2 are fascinating. It could be interesting to use the experiment to corroborate the postulate from Hoover et al. that pathological tau is relocalized (accumulated in) to dendrites.

    References:

    Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010 Dec 22;68(6):1067-81. PubMed.

    View all comments by Jan Pedersen

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Time to Take the "Phospho" out of Tau?